Swedbank Ab Ultragenyx Pharmaceutical Inc. Transaction History

Swedbank Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Dec 09, 2024	SELL	$34.92 - $46.66 $468,312 - $625,757	-13,411 Closed	0 $0
Q2 2022 Dec 09, 2024	SELL	$45.8 - $85.4 $1.13 Million - $2.1 Million	-24,600 Reduced 64.72%	13,411 $800,000
Q1 2022 Dec 09, 2024	BUY	$62.2 - $84.4 $193,504 - $262,568	3,111 Added 8.91%	38,011 $2.76 Million
Q3 2021 Dec 09, 2024	SELL	$77.92 - $102.4 $412,976 - $542,720	-5,300 Reduced 13.18%	34,900 $3.15 Million
Q1 2021 Dec 09, 2024	BUY	$106.9 - $167.73 $4.3 Million - $6.74 Million	40,200 New	40,200 $4.58 Million

326

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.44B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

Stay updated on Swedbank Ab with notifications on news.